“…It Is Time to Reconsider the Blood Pressure Targets in Patients With Type 2 Diabetes? Paolo Verdecchia , Gianpaolo Reboldi , Fabio Angeli I n this issue of the Hypertension, Yang et al 1 present the results of a network meta-analysis of 30 trials conducted in 59 934 total patients with type 2 diabetes. Eighteen trials compared antihypertensive drugs versus placebo, or dual agents versus a single agent, and 12 trials compared different blood pressure (BP) targets.…”